Table 1.
Summary of Typhoid Vaccine Acceleration Consortium (TyVAC) Clinical Trials (as of 12 December 2019)
| Country | Design | Control Vaccine | Ages | Start Date | Duration | No. Vaccinated |
|---|---|---|---|---|---|---|
| Nepal | Individually randomized efficacy trial | Capsular group A meningococcal conjugate vaccine | 9 mo–16 y | Nov 2017 | 2 ya | 20 019 |
| Malawi | Individually randomized efficacy trial | Capsular group A meningococcal conjugate vaccine | 9 mo–12 y | Feb 2018 | 2–2.5 yb | 28 142 |
| Bangladesh | Cluster-randomized effectiveness trial | Live attenuated Japanese encephalitis | 9 mo–16 y | Apr 2018 | 2 y | 67 395 |
| Burkina Faso | Individually randomized immunogenicity trial | Inactivated poliovirus vaccine | 9–23 mo | Nov 2018 | 9 mo | 250 |
aCase-driven interim efficacy.
bCase-driven design with a minimum of 2 years of follow-up.